School of Medicine


Showing 11-20 of 47 Results

  • Corinne Beinat

    Corinne Beinat

    Assistant Professor of Radiology (Molecular Imaging Program at Stanford)

    Current Research and Scholarly InterestsThe focus of my research is to develop novel imaging and treatment strategies to detect and better manage cancer. This approach relies first on the identification and validation of molecular targets and biomarkers that are linked with underlying the underlying biology driving the initiation and progression of cancers. We then develop novel small molecule based radiotracers to monitor fundamental molecular and cellular processes occurring in living subjects using positron emission tomography (PET) with the goal of improving cancer diagnosis and management. We additionally develop novel peptide based theragnostic agents for stratification of patients with high receptor expression, treatment with targeted radionuclide therapy, and subsequent monitoring of treatment response. Our overall goal is to develop multiple clinically translatable strategies to improve cancer diagnosis, management, and outcomes.

  • Gill Bejerano

    Gill Bejerano

    Professor of Developmental Biology, of Computer Science, of Pediatrics (Genetics) and of Biomedical Data Science

    Current Research and Scholarly Interests1. Automating monogenic patient diagnosis.
    2. The genomic signatures of independent divergent and convergent trait evolution in mammals.
    3. The logic of human gene regulation.
    4. The reasons for sequence ultraconservation.
    5. Cryptogenomics to bridge medical silos.
    6. Cryptogenetics to debate social injustice.
    7. Managing patient risk using machine learning.
    8. Understanding the flow of money in the US healthcare system.

  • Sean Bendall

    Sean Bendall

    Associate Professor of Pathology

    Current Research and Scholarly InterestsOur goal is to understand the mechanisms regulating the development of human systems. Drawing on both pluripotent stem cell biology, hematopoiesis, and immunology, combined with novel high-content single-cell analysis (CyTOF – Mass Cytometry) and imagining (MIBI-Multiplexed Ion Beam Imaging) we are creating templates of ‘normal’ human cellular behavior to both discover novel regulatory events and cell populations as well as understand dysfunctional processes such as cancer.

  • Catherine Benedict, PhD

    Catherine Benedict, PhD

    Clinical Associate Professor, Psychiatry and Behavioral Sciences - Medical Psychiatry

    Current Research and Scholarly InterestsMy research focuses on improving cancer survivorship through better understanding of long-term health outcomes and through the development of theoretically driven, evidence-based behavioral interventions to improve adjustment, risk management, and quality of life. To this end, I lead studies aimed to guide and support patient decision-making and self-management after cancer. Much of my work focuses on the experiences of young adults affected by cancer.

  • Jonathan S. Berek, MD, MMSc

    Jonathan S. Berek, MD, MMSc

    Laurie Kraus Lacob Professor

    BioLaurie Kraus Lacob Professor
    Stanford University School of Medicine

    Director, Stanford Women’s Cancer Center
    Senior Advisor, Stanford Cancer Institute

    Executive Director, Stanford Health Communication Initiative
    Director, MedArts Films
    Stanford Center for Health Education
    Stanford University

  • Dominique Bergmann

    Dominique Bergmann

    Shirley R. and Leonard W. Ely, Jr. Professor of the School of Humanities and Sciences

    Current Research and Scholarly InterestsWe use genetic, genomic and cell biological approaches to study cell fate acquisition, focusing on cases where cell fate is correlated with asymmetric cell division.

  • Daniel Bernstein

    Daniel Bernstein

    Alfred Woodley Salter and Mabel G. Salter Endowed Professor of Pediatrics

    Current Research and Scholarly Interests1. Using iPSC-derived cardiomyocytes to understand hypertrophic cardiomyopathy and heart failure associated with congenital heart disease.
    2. Role of alterations in mitochondrial dycamics and function in normal physiology and disease.
    3. Differences between R and L ventricular responses to stress,
    4. Immune biomarkers of risk after pediatric VAD implantation.
    5. Biomarkers for post-transplant lymphoproliferative disorder.

  • Alice Bertaina MD, PhD

    Alice Bertaina MD, PhD

    Lorry I. Lokey Professor

    Current Research and Scholarly InterestsDr. Bertaina is a highly experienced clinician and will play a key role in supporting Section Chief Dr. Rajni Agarwal and Clinical Staff in the Stem Cell Transplant Unit at Lucile Packard Children’s Hospital. She will also continue her research on immune recovery and miRNA, understanding the mechanisms underlying immune reconstitution, Graft-versus-Host Disease (GvHD), and leukemia relapse after allogeneic HSCT in pediatric patients affected by hematological malignant and non-malignant disorders.

  • Carolyn Bertozzi

    Carolyn Bertozzi

    Baker Family Director of Sarafan ChEM-H, Anne T. and Robert M. Bass Professor in the School of Humanities and Sciences and Professor, by courtesy, of Chemical and Systems Biology and of Radiology

    BioCarolyn Bertozzi is the Baker Family Director of Sarafan ChEM-H, Anne T. and Robert M. Bass Professor in the School of Humanities and Sciences and Professor, by courtesy, of Chemical and Systems Biology and of Radiology at Stanford University, and an Investigator of the Howard Hughes Medical Institute. She completed her undergraduate degree in Chemistry from Harvard University in 1988 and her Ph.D. in Chemistry from UC Berkeley in 1993. After completing postdoctoral work at UCSF in the field of cellular immunology, she joined the UC Berkeley faculty in 1996. In June 2015, she joined the faculty at Stanford University and became the co-director and Institute Scholar at Sarafan ChEM-H.

    Prof. Bertozzi's research interests span the disciplines of chemistry and biology with an emphasis on studies of cell surface glycosylation pertinent to disease states. Her lab focuses on profiling changes in cell surface glycosylation associated with cancer, inflammation and bacterial infection, and exploiting this information for development of diagnostic and therapeutic approaches, most recently in the area of immuno-oncology.

    Prof. Bertozzi has been recognized with many honors and awards for both her research and teaching accomplishments. She is an elected member of the National Academy of Sciences, the American Academy of Arts and Sciences, and the German Academy of Sciences Leopoldina. Some awards of note include the Nobel Prize in Chemistry, Lemelson-MIT award for inventors, Whistler Award, Ernst Schering Prize, MacArthur Foundation Fellowship, the ACS Award in Pure Chemistry, Tetrahedron Young Investigator Award, and Irving Sigal Young Investigator Award of the Protein Society. Her efforts in undergraduate education have earned her the UC Berkeley Distinguished Teaching Award and the Donald Sterling Noyce Prize for Excellence in Undergraduate Teaching.

  • Allison Betof Warner, MD, PhD

    Allison Betof Warner, MD, PhD

    Assistant Professor of Medicine (Oncology)

    BioDr. Betof Warner is a board-certified, fellowship-trained medical oncologist with the Cutaneous Oncology Program and an Assistant Professor in the Department of Medicine, Division of Medical Oncology. She also serves as Director of Melanoma Medical Oncology, Director of Solid Tumor Cellular Therapy, and co-Director of the Pigmented Lesion and Melanoma Program.

    Clinical interests of Dr. Betof Warner include treatment of advanced melanoma, immunotherapy, and cellular therapies for solid tumors. She has been a pioneer in the use of commercial tumor infiltrating lymphocyte (TIL) therapy, which is expected to become standard of care for immunotherapy-refractory melanoma.

    Dr. Betof Warner serves as the leader of the Melanoma & Cutaneous Oncology Clinical Research Group, with research interests focused on tumor response to immunotherapy. She has been the principal investigator of multiple clinical trials focusing on immunotherapy-refractory melanoma and is internationally recognized for her expertise in central nervous system metastases and the use of novel cellular therapies. Dr. Betof Warner collaborates with investigators around the world in surgery, neuro-oncology, neurosurgery, radiation oncology, and pathology. She has received funding and awards for her clinical and translational investigative work from multiple high-profile organizations, including the American Society of Clinical Oncology (ASCO), National Institutes of Health (NIH), and Melanoma Research Foundation.

    In addition to publishing her research in peer-reviewed journals, Dr. Betof Warner has served as an editorial and grant reviewer for multiple organizations, including the Melanoma Research Foundation. She has authored book chapters and case reports, contributed to national guidelines, and presented her findings at regional, national, and international meetings.

    Dr. Betof Warner is a member of multiple professional organizations and societies, including the American Association for Cancer Research, the American Society of Clinical Oncology, and the Society for Immunotherapy of Cancer, where she serves on the Early Career Scientist Committee. She is also a member of the American College of Sports Medicine and the European Society for Medical Oncology.